Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Imb Dx Inc. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are assigned to 3 distinct examiners, resulting in a one-to-one ratio of pending matters to examining personnel. The prosecution activity is organized within 2 distinct art units, suggesting that the company's biotechnological innovations are concentrated in a few specific technical niches.
JONATHAN EDWARD HAYES is the busiest examiner for this portfolio, though he is currently responsible for only 1 pending office action. This even distribution across 3 distinct examiners prevents any single official from having a controlling influence over the company's pending applications. The use of 2 distinct art units for 3 pending office actions indicates that at least two of the examiners are likely working within the same administrative group at the patent office.
For practitioners, this data suggests a need to coordinate strategies across 3 distinct examiners while adhering to the specific requirements of 2 distinct art units. Because JONATHAN EDWARD HAYES and the other 2 examiners each handle 1 pending office action, the portfolio's progress is not bottlenecked by any one individual. The focus on 2 distinct art units suggests that the company's current filings are technically related enough to be reviewed by a limited number of specialized divisions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAYES, JONATHAN EDWARD | 1 | 36.3% | +23.5% |
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
| NGUYEN, PETER | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027425 | METHOD OF PREDICTING CANCER RECURRENCE USING PATIENT-SPECIFIC PANEL | SALMON, KATHERINE D | 28d overdue |
| 18027792 | METHOD FOR PREPARATION OF MULTI-ANALYTICAL PREDICTION MODEL FOR CANCER DIAGNOSIS | HAYES, JONATHAN EDWARD | — |
| 18025529 | METHOD OF IDENTIFYING FALSE POSITIVE VARIANTS IN NUCLEIC ACID SEQUENCING | NGUYEN, PETER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027425 | METHOD OF PREDICTING CANCER RECURRENCE USING PATIENT-SPECIFIC PANEL | SALMON, KATHERINE D | 28d overdue |
| 18027792 | METHOD FOR PREPARATION OF MULTI-ANALYTICAL PREDICTION MODEL FOR CANCER DIAGNOSIS | HAYES, JONATHAN EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1685 | 2 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18027792 | METHOD FOR PREPARATION OF MULTI-ANALYTICAL PREDICTION MODEL FOR CANCER DIAGNOSIS | HAYES, JONATHAN EDWARD | 1685 | §101§103§112 | Non-Final OA | — | Pending | Mar 22, 2023 |
| 18027425 | METHOD OF PREDICTING CANCER RECURRENCE USING PATIENT-SPECIFIC PANEL | SALMON, KATHERINE D | 1682 | §101§102§112 | Final Rejection | 28d overdue | Pending | Mar 21, 2023 |
| 18025529 | METHOD OF IDENTIFYING FALSE POSITIVE VARIANTS IN NUCLEIC ACID SEQUENCING | NGUYEN, PETER | 1685 | §101§103§112 | Non-Final OA | — | Pending | Mar 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImb Dx Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Jonathan Edward Hayes has the most, with 1 of Imb Dx Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
